Humanized monoclonal antibodies have transformed the treatment of patients with lymphomas. The first application of these new drugs appeared less than 10 years ago but currently one patient will certainly receive them once or several time during the evolution of his disease. This review will cover the use of these monoclonal antibodies alone or in combination with chemotherapy. Rituximab, an unconjugated anti-CD20 chimeric antibody, is certainly the most widely used but other unconjugated or radiolabeled monoclonal antibodies catch up quickly. If there are randomized studies demonstrating the benefit of adding these drugs to the treatment of patients with lymphoma, very few studies have compared the activity of the different monoclonal antibodies. A lot of questions needs to be answered before the best setting of these drugs will be known.

中文翻译：

---

单克隆抗体联合化疗可治疗淋巴瘤患者。

人源化单克隆抗体已经改变了淋巴瘤患者的治疗方法。这些新药的首次应用出现在不到10年前，但是目前，一名患者在疾病发展过程中肯定会接受一次或几次。这篇综述将涵盖这些单克隆抗体单独使用或与化学疗法结合使用的情况。利妥昔单抗是一种未缀合的抗CD20嵌合抗体，无疑是使用最广泛的抗体，但其他未缀合或放射性标记的单克隆抗体很快就会流行起来。如果有随机研究表明将这些药物添加到淋巴瘤患者的治疗中获益，那么很少有研究比较不同单克隆抗体的活性。在知道这些药物的最佳设置之前，需要回答很多问题。